Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) engages in the research, development, production, and sale of biological and biochemical injections in China. The company offers core products covering cardiovascular and cerebrovascular diseases, immune diseases including anti-tumor applications, neurological diseases, and other therapeutic varieties; it also researches and produces raw materials, traditional Chinese medicine extracts, Chinese and Western medicine preparations, bio-organic fertilizers, and bio-feeds while providing consulting, venture capital, and equity investment services. Founded in 1999 and headquartered at No. 8 Xingsheng Street, Beijing Economic and Technological Development Zone, Beijing, China, the company operates primarily across domestic regions including East China, Northeast China, Central China, Northern China, Southwest China, South China, and Northwestern China. Subsidiaries include Beijing Luzhu Biotechnology Co., Ltd., in which it holds a 6.79% stake. Recent developments encompass approval for site relocation in July 2025, a subsidiary's transfer of a protein production project for 20 million yuan in June 2025, an agreement to acquire a 5.6664% stake in Suzhou Inhal Pharma Co., Ltd., and the release of its 2025 semi-annual report along with third-quarter performance disclosures.